Chinese API Manufacturer Cited for Quality Shortcomings

International Pharmaceutical Regulatory Monitor
A A
The FDA issued a warning letter to Zhuhai United Laboratories, an active pharmaceutical ingredient firm based in Zhuhai, China, taking the facility to task for failure to investigate out-of-specification results and to correct critical CGMP deviations.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00